{"schema":"hottub-news/story/v1","story":"st_hmv726gj4e24ig6slffa","title":"Small Molecule Drug Discovery - Global Strategic Business Report Forecasts Growth from $61.5B (2024) to $100B by 2030, Profiling AstraZeneca, Gilead Sciences, Merck & Pfizer","title_en":null,"outlets":1,"brief":null,"page":"https://hottub.news/stories/small-molecule-drug-discovery-global-strategic-business-report-hmv726gj4e","count":1,"items":[{"id":"n_hmv726gj4e24ig6slffa","seq":628272,"kind":"press_release","title":"Small Molecule Drug Discovery - Global Strategic Business Report Forecasts Growth from $61.5B (2024) to $100B by 2030, Profiling AstraZeneca, Gilead Sciences, Merck & Pfizer","url":"https://www.globenewswire.com/news-release/2026/09/29/3370541/28124/en/small-molecule-drug-discovery-global-strategic-business-report-forecasts-growth-from-61-5b-2024-to-100b-by-2030-profiling-astrazeneca-gilead-sciences-merck-pfizer.html","summary":"AI, computational design and high-throughput screening are accelerating discovery, while targeted therapies, outsourcing and Asia-Pacific expansion create opportunities. AI, computational design and high-throughput screening are accelerating discovery, while targeted therapies, outsourcing and Asia-Pacific expansion create opportunities.","published":"2026-09-29T09:22:00Z","seen":"2026-09-29T09:30:50Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business"],"entities":[{"id":"Q731938","name":"AstraZeneca","type":"org"},{"id":"Q663596","name":"Gilead Sciences","type":"org"},{"id":"Q96472579","name":"Merck","type":"org"},{"id":"Q206921","name":"Pfizer","type":"org"}],"story":"st_hmv726gj4e24ig6slffa","category":"economy-business","category_p":0.7200000286102295,"sentiment":"neutral","tone":0.27000001072883606,"political":0.009999999776482582}]}